이식형 제세동기 : 시장 점유율 분석, 산업 동향 및 통계, 성장 예측(2024-2029년)

The Implantable Defibrillators Market size is estimated at USD 4.05 billion in 2024, and is expected to reach USD 5.52 billion by 2029, growing at a CAGR of 5.70% during the forecast period (2024-2029).

COVID-19 significantly impacted the implantable defibrillator market during the pandemic due to the rise in cardiac arrest among COVID-19 patients. The market declined during the initial pandemic but increased due to the demand for implantable defibrillators in COVID-19 patients. For instance, according to the study published in the Journal of Cardiac Failure in June 2022, implantable cardioverter defibrillators (ICDs) implanted in patients with heart failure provided helpful information on markers of cardiac status such as atrial fibrillation (AF). Thus, it was expected to increase adoption of implantable defibrillators during the COVID-19 pandemic, thereby driving market growth during the late pandemic.

The factors driving the growth of the implantable defibrillators market include the increasing prevalence of cardiac arrhythmias such as ventricular fibrillation, ventricular tachycardia, and other heart diseases such as myocardial infarction or congenital heart diseases.

The rising prevalence of heart diseases such as heart failure is anticipated to drive market growth. For instance, according to the American Heart Association's annual report in 2022, the prevalence rate of heart failure in the United States was around 6 million in 2021, accounting for 1.8% of the total population. Furthermore, according to the Centers for Disease Control and Prevention, in July 2023, the percentage of adults aged 18 and over living with myocardial infarction in the United States in 2022 was 3% of the total population. Such a massive prevalence of myocardial infarction is anticipated to increase the adoption of implantable defibrillators, driving market growth.

In addition, according to the British Heart Foundation, in August 2022, around 7.6 million people in the United Kindom suffered from heart and circulatory diseases 2022. The massive prevalence of cardiovascular disease in developed countries such as the United Kingdom escalates the demand for implantable defibrillators, fueling the target market growth in the studied period.

The rising technological advancements and improved success rates of implantable defibrillators in recent years are anticipated to boost market growth further. For instance, in August 2022, clinical research presented by Medtronic PLC demonstrated the effectiveness of a novel minimally invasive defibrillator implant (Medtronic EV ICD system) intended to stop a sudden cardiac arrest. The extravascular implantable defibrillator system, which includes its primary component under the left armpit, offers backup pacing therapy to reduce vibrations, prevent tachycardia, and help patients avoid defibrillation shock.

Therefore, the increasing prevalence of cardiac arrhythmia and other heart diseases is expected to increase the demand for implantable defibrillators for early access to cardiac arrest. It is further expected to boost the growth of the studied market over the forecast period. However, the stringent regulatory framework for implantable defibrillators is anticipated to impede market growth.

Implantable Defibrillators Market Trends

Subcutaneous Implantable Cardioverter Defibrillator (S-ICD) is Anticipated to Show the Fastest Growth Over the Forecast Period.

The Subcutaneous Implantable Cardioverter Defibrillator (S-ICD) effectively senses, discriminates, and converts ventricular tachycardia/ventricular fibrillation using a subcutaneous electrode to analyze the heart rhythm. It is an established therapy for preventing sudden cardiac death and an alternative to a transvenous implantable cardioverter-defibrillator (ICD) system in selected patients.

The factors driving the segment's growth include the rising initiatives from the key market players and the increasing awareness of S-ICD among people.

Key market players are constantly working to identify the safety and effectiveness of subcutaneous implantable defibrillators, which are anticipated to drive segment growth. For instance, in December 2021, Boston Scientific Corporation conducted a study on S-ICD to assess the subcutaneous implantable defibrillator's efficacy, performance, and safety. The findings suggested that the S-ICD system prevents many difficulties connected with leads inserted in those locations because it offers protection without touching the heart or substernal area.

Furthermore, the various advantages of subcutaneous implantable defibrillators are anticipated to propel segment growth. For instance, according to the study published in the Arrhythmia & Electrophysiology Review (AER) Journal in July 2021, S-ICDs help patients avoid many of the short and long-term dangers of de novo implantation, including pneumothorax and heart perforation, and systemic infection. Additionally, S-ICDs underwent multicentre clinical studies where they demonstrated their efficacy, and new findings indicated that they might even be superior to Transvenous ICDs in some circumstances. Therefore, benefits associated with subcutaneous implantable defibrillators increase the demand and drive the growth of the segment studied.

Therefore, owing to the significant benefits of subcutaneous implantable defibrillators, the segment is anticipated to grow fastest over the forecast period.

North America is Expected to Hold a Major Share of the Studied Market Over the Forecast Period

North America is expected to hold a significant share of the overall implantable defibrillators market throughout the forecast period. It is due to the high healthcare expenditures, rising awareness of ICD's effectiveness in cardiovascular disorders such as arrhythmias, flutters, and fibrillations, and the presence of major key market players in the region.

Furthermore, the United States defibrillator market is growing within North America due to rising technological advancements through partnerships and the supportive reimbursement policy. In addition, the increase in government funding for cardiovascular diseases and the increase in research and development activities, among others, will drive the adoption of implantable defibrillators in the United States, driving market growth.

The rising prevalence of cardiovascular diseases (CVD), such as arrhythmias, among the population of the United States led to increased adoption of defibrillators for proper disease management. For instance, according to the Arrhythmia Alliance Report 2023, about 1 in 50 Americans under age 65, whereas 1 in 10 Americans over age 65 suffer from atrial fibrillation annually, and around 1 in 2,100 persons experience ventricular arrhythmias in the United States annually. Therefore, the considerable incidence of arrhythmia is projected to boost the demand for implantable defibrillators, which is anticipated to drive market growth.

Moreover, the rising adoption of implantable defibrillators in the hospitals and clinics of the United States is anticipated to drive market growth in the region. For instance, in December 2021, as part of an international clinical trial, Cleveland Clinic successfully implanted leadless pacemaker defibrillator systems in the first two patients in the world. The innovative device, which promises to provide treatment for low and increased heart rates, combines the technology of a leadless pacemaker with a subcutaneous implantable cardioverter defibrillator.

Therefore, the rising adoption of implantable defibrillators and the increasing prevalence of cardiac rhythm disorders in the region is anticipated to drive market growth.

Implantable Defibrillators Industry Overview

The market for implantable defibrillators is highly consolidated with established market players. The factors owing to the competition include the rising research and development on implantable defibrillators, rising approvals from regulatory agencies, and the key initiatives adopted by the market players. Some players operating in the market include Boston Scientific Corporation, Microport Scientific Corporation, Medtronic PLC, Abbott, and Biotronik, among others.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Increasing Prevalence of Cardiac Arrhythmia and Other Heart Diseases.
  • 4.2.2 Technological Advancements in the Field of Implantable Defibrillators
• 4.3 Market Restraints
  • 4.3.1 Stringent Regulatory Framework
• 4.4 Porter's Five Forces Analysis
  • 4.4.1 Bargaining Power of Suppliers
  • 4.4.2 Bargaining Power of Buyers/Consumers
  • 4.4.3 Threat of New Entrants
  • 4.4.4 Threat of Substitute Products
  • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD)

• 5.1 By Type
  • 5.1.1 Singel Chambered
  • 5.1.2 Dual Chambered
  • 5.1.3 Biventricular (cardiac resynchronization therapy)
• 5.2 By Route
  • 5.2.1 Transvenous/Traditional ICD
  • 5.2.2 Subcutaneous (S-ICD)
• 5.3 By End User
  • 5.3.1 Hospitals
  • 5.3.2 Speciality Clinics
  • 5.3.3 Ambulatory Surgical Centers
• 5.4 Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

• 6.1 Company Profiles
  • 6.1.1 Boston Scientific Corporation
  • 6.1.2 LivaNova PLC
  • 6.1.3 Microport Scientific Corporation
  • 6.1.4 Medtronic Plc
  • 6.1.5 Abbott
  • 6.1.6 Biotronik

7 MARKET OPPORTUNITIES AND FUTURE TRENDS